Showing results (91-100 of 97) with videos related to
Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 97 results.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 InfectionChloe Orkin, Keikawus Arasteh, Miguel Górgolas Hernández-Mora, et al.The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionSusan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, et al.The Lancet. HIV|April 1, 2021
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR studyChloe Orkin, Shinichi Oka, Patrick Philibert, et al.European Urology|October 19, 2016
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell CarcinomaJames J Hsieh, David Chen, Patricia I Wang, et al.Lancet (London, England)|December 14, 2020
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 2, 2020
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR TrialsGiuliano Rizzardini, Edgar T Overton, Chloe Orkin, et al.Pageof 10